English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, March 12, 2019
エーザイ、米国FDAが不眠障害治療薬「レンボレキサント」の新薬承認申請を受理
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
Thursday, March 7, 2019
エーザイ、不眠障害治療薬「レンボレキサント」について日本において新薬承認申請書を提出
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan
Wednesday, February 27, 2019
エーザイ、国際NGO「難民を助ける会」とスーダンでの活動を支援する契約を締結
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan
Thursday, February 21, 2019
アッヴィとエーザイ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」について国内で初めて化膿性汗腺炎の適応追加承認を取得
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
Wednesday, February 13, 2019
エーザイ、抗てんかん剤「Fycompa(R)」について欧州において小児てんかんに係る適応で承認申請を提出
Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy

Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8400